Vancouver, British Columbia–(Newsfile Corp. – February 6, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial …
Read More »
Breaking News
- Mont Royal Announces Agreement with Port Saguenay for the Ashram Rare Earths Project
- Lithosphere Enhances Developer Tooling to Support Scalable Decentralized Applications
- CSE Bulletin: Delist – FinCanna Capital Corp. (CALI.X)
- Benz Announces that Icon Delivers Shallow High-Grade Discovery as Large-Scale System Continues to Grow
- BluMetric Announces Fiscal Year 2025 Financial Results
- Silverco Provides Additional Information on the Agreement to Acquire Nuevo Silver and the La Negra Mine in Querétaro Mexico
- Sankamap Provides Update on Late Filing of Financial Statements
- K2 Gold Announces Non-Brokered Private Placement to Raise up to CAD $15 Million
- Legend Power Systems Schedules Fiscal 2025 Financial Results Release and Webinar
- Puranium Energy Announces Share Consolidation
Matribhumi Samachar
Address : 125 - Rajiv Nagar, Vinayakpur, Kanpur - 208025
Mo. No.: 8303063085
Email: [email protected]
Managed By Y2KSOLUTION
Copyright © Matribhumi Samachar